Ticker

No recent analyst price targets found for MVPT.

Latest News for MVPT

Napco Security: How The MVP Platform Secures Napco's Future

Napco Security Technologies is transitioning from hardware to a SaaS model, with recurring service revenue now comprising 51% of total sales at 90%+ gross margins. I assign NSSC a buy rating and a $50 per share target, citing robust operating leverage, a debt-free balance sheet, and strong free cash flow generation. The imminent MVP cloud platform launch is expected to catalyze high-margin recurring revenue growth,…

Seeking Alpha • Jul 21, 2026
BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer

Unique MRI Study Shows How the Combination Exerts its Effect   VANCOUVER, BC – TheNewswire - May 1, 2026 – TheNewswire - BioVaxys Technology Corp. (CSE: BIOV OTCQB:BVAXF FRA:5LB0), a clinical-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication of a study that further validates the immune response mechanism from a combination of its…

TheNewswire • May 1, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for MVPT.

No Senate trades found for MVPT.

No House trades found for MVPT.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top